We joined COST Action CA24162 (AdResCanCER)

Dr. Abdulkadir Gumuscu has joined COST Action CA24162, Adaptive and Acquired Resistance in Gastrointestinal Cancers – Contemporary and Emerging Resolutions (AdResCanCER), as a working group member. The Action runs from October 2025 to October 2029 and is funded by COST (European Cooperation in Science and Technology).
Gastrointestinal cancers, including oesophageal, gastric, colorectal, pancreatic and liver cancers, are often hard to treat because tumours become resistant to chemotherapy. AdResCanCER brings together researchers, clinicians, early-career investigators and companies across Europe to understand this resistance and develop new ways to overcome it.
Within the network, our group contributes to the development of standardized machine learning workflows and multi-layered analysis of high-dimensional data. This work builds on our experience in feature selection for high-dimensional data and machine learning for health applications.
We look forward to working with partners across Europe and to opening collaboration and training opportunities for our students.